Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Stem Cell Transplantation
100%
Immune Reconstitution
100%
Survival Outcomes
100%
Thymoglobulin
100%
Serotherapy
100%
Alemtuzumab
100%
Antithymocyte Globulin
70%
Hematopoietic Stem Cell Transplantation
30%
T Cells
30%
Event-free Survival
20%
Reconstitution
20%
Natural Killer Cells
20%
Conditioning Regimen
20%
Drug Exposure
20%
Malignant Hematological Diseases
20%
High Risk
10%
Overall Survival
10%
Graft-versus-host Disease (GvHD)
10%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
10%
Transplantation
10%
Low Risk
10%
Pharmacokinetic Analysis
10%
Disease Risk
10%
Large Cohort
10%
Immune System
10%
T-cell Recovery
10%
CD4+ T Cell Subsets
10%
Cox Proportional Hazards Regression Analysis
10%
Human Adenovirus (HAdV)
10%
Disease Relapse
10%
Survival Risk
10%
Fast Recovery
10%
Donor chimerism
10%
CD8 T Cell Subsets
10%
Epstein-Barr Virus Reactivation
10%
Immunology and Microbiology
Anti-Thymocyte Globulin
100%
Immune Reconstitution
100%
Stem Cell Transplantation
100%
Alemtuzumab
100%
T Cell
40%
Hematopoietic Stem Cell Transplantation
30%
Natural Killer Cell
20%
Event Free Survival
20%
Drug Exposure
20%
Conditioning
20%
Allogeneic Hematopoietic Stem Cell Transplantation
10%
Cytotoxic T-Cell
10%
Overall Survival
10%
Acute Graft Versus Host Disease
10%
Immune System
10%
Pharmacokinetics
10%
T Cell Subset
10%
CD4
10%
Human Adenovirus C
10%
Pharmacodynamics
10%
Chimera
10%
Virus Reactivation
10%
CD3 Antigen
10%
Epstein Barr Virus
10%
Pharmacology, Toxicology and Pharmaceutical Science
Thymocyte Antibody
100%
Alemtuzumab
100%
Event Free Survival
20%
Disease
10%
Overall Survival
10%
Pharmacodynamics
10%
Cohort Study
10%
CD8 Antigen
10%
Acute Graft Versus Host Disease
10%
Epstein-Barr Virus
10%
Hematologic Disease
10%
Human Adenovirus C
10%
Pharmacokinetics
10%
Lead Poisoning
10%
CD3 Antigen
10%